RT @AlzamendNeuro: ALZN002 is an immunotherapeutic dendritic cell-based vaccine anticipated to begin Phase I/IIA trial in Q1. The inventor…
2,310 followers
28 followers
RT @AlzamendNeuro: ALZN002 is an immunotherapeutic dendritic cell-based vaccine anticipated to begin Phase I/IIA trial in Q1. The inventor…
1,332 followers
ALZN002 is an immunotherapeutic dendritic cell-based vaccine anticipated to begin Phase I/IIA trial in Q1. The inventor of ALZN002 is one of the authors of this publication.. #Alzheimers $ENDALZ $ALZN https://t.co/zS4Frjo8i6
10,165 followers
RT @AlzamendNeuro: ALZN002 is a journey that started nearly 20 years ago. We recently received a “Study May Proceed” Letter from the FDA to…